They have no fiduciary duty in many cases and can profit from customers’ confusion. But where’s the line between unsavory and illegal?
Related Posts
Wall Street’s Slide Resumes as Tariff Anxiety Persists for Investors
The S&P 500 is on the cusp of closing in a correction, or a 10% drop from its February high. Constantly moving goal posts on […]
As 23andMe Struggles, Concerns Surface About Its Genetic Data
- Andrew Kwenz
- October 6, 2024
- 0
A plummet in the company’s valuation and a recent board resignation have raised questions about the future of genetic data collected from millions of customers.
Struggling With Errors, DOGE Deletes Billions More From List of Savings
For the second time in a week, Elon Musk’s government overhaul effort updated its “wall of receipts” to remove mistakes that inflated its success.